Posterior Uveitis & Panuveitis: Overview

Overview

Posterior uveitis refers to inflammation predominantly involving the choroid and/or retina (chorioretinitis, retinitis, or choroiditis), while panuveitis describes inflammation involving the anterior chamber, vitreous, and posterior segment simultaneously, without one anatomic site clearly predominating. Together these anatomic categories are frequent, visually significant forms of uveitis with etiologies spanning infectious, autoimmune, and idiopathic causes.

Epidemiology & Risk Factors

In a large single-center cohort study from an HTLV-1 (human T-cell leukemia virus type 1) endemic area of Japan, panuveitis was the most frequent anatomic category overall (47.1% of cases), followed by anterior uveitis (42.1%); HTLV-1-associated uveitis was the single most common etiology (10.5%), followed by sarcoidosis (10.4%) and Vogt-Koyanagi-Harada (VKH) disease (8.7%).¹ While these specific proportions reflect a regionally distinctive population, the broader lesson — that posterior uveitis and panuveitis encompass a wide range of infectious and systemic autoimmune etiologies whose relative frequency varies by geography — applies broadly. Risk factors are therefore etiology-specific: for example, ethnicity (VKH disease is more common in Asian, Hispanic, and Middle Eastern populations with pigmented tissue) and systemic disease history (sarcoidosis, Behçet's disease) shape the differential in a given patient.

Pathophysiology

The pathophysiology of posterior uveitis and panuveitis varies fundamentally by cause. Infectious forms (e.g., HTLV-1-associated uveitis, viral retinitis, toxoplasmosis) reflect direct pathogen-driven inflammation or a virus/pathogen-triggered immune response. Autoimmune/systemic forms reflect distinct immunopathologic mechanisms: VKH disease involves T-cell-mediated autoimmunity against melanocyte antigens shared by the eye, inner ear, meninges, and skin, producing a granulomatous panuveitis; sarcoidosis produces non-caseating granulomatous inflammation that can affect any part of the uveal tract; and Behçet's disease produces an occlusive retinal vasculitis as part of a systemic vasculitic process. This etiologic diversity is why posterior uveitis/panuveitis requires a fundamentally different, more systemic diagnostic approach than anterior uveitis.

Clinical Presentation

Presentation depends heavily on etiology but commonly includes blurred vision, floaters, and in some cases photopsias or scotomas from focal chorioretinal lesions. Panuveitis often additionally produces the anterior segment symptoms of pain, redness, and photophobia layered on top of posterior segment findings. VKH disease classically presents with bilateral panuveitis, sometimes preceded by a prodromal meningismus-like phase (headache, tinnitus, or hearing changes) and followed by later integumentary changes (vitiligo, poliosis) in the chronic/convalescent stage.

Exam Findings

• Chorioretinal lesions, ranging from focal (as in toxoplasmosis) to diffuse (as in VKH or sympathetic ophthalmia)
• Vitritis, often present regardless of specific posterior etiology
• Retinal vasculitis (sheathing, occlusion) especially prominent in Behçet's disease
• Exudative retinal detachment in acute VKH disease, from diffuse choroidal inflammation
• Disc edema or hyperemia in several etiologies (VKH, sarcoidosis)
• Worse presenting visual acuity in posterior uveitis and panuveitis compared with anterior or intermediate uveitis, reflecting the direct involvement of vision-critical structures¹
• Inflammatory choroidal neovascular membrane (CNVM), an important complication in chronic VKH disease, more often chronic-recurrent than initial-onset acute VKH²

Differential Diagnosis

• Infectious posterior uveitis (toxoplasmosis, viral retinitis, tuberculosis, syphilis, HTLV-1-associated uveitis)
• VKH disease (bilateral, granulomatous, with systemic prodrome and later integumentary findings)
• Sarcoidosis-associated uveitis (may have systemic pulmonary or other organ involvement)
• Behçet's disease (occlusive retinal vasculitis, oral/genital ulcers, and other systemic vasculitic features)
• Masquerade syndromes (intraocular lymphoma), particularly in atypical or treatment-resistant cases

Management

Diagnosis rests on a combination of anatomic classification (using standardized nomenclature), etiologic workup (targeted serology, imaging, and, where indicated, intraocular fluid analysis), and recognition of systemic disease associations. Visual acuity at onset is worse in posterior uveitis and panuveitis than in anterior or intermediate uveitis, but posterior uveitis and panuveitis also show significant visual acuity improvement by 1 year with appropriate treatment, in contrast to anterior and intermediate uveitis, which tend to improve more gradually over about 3 years.¹ Among major etiologies, Behçet's disease carries the worst long-term (10-year) visual prognosis, underscoring the importance of early, aggressive, etiology-specific treatment in this condition specifically.¹

Treatment is etiology-directed: infectious causes require targeted antimicrobial therapy (often combined with corticosteroids to control the associated inflammatory response), while autoimmune/idiopathic forms (VKH, sarcoidosis, Behçet's) are managed with systemic corticosteroids and, for chronic or severe disease, steroid-sparing immunomodulatory or biologic therapy. In VKH disease specifically, ongoing surveillance for inflammatory CNVM is warranted, particularly in chronic-recurrent disease, since anti-VEGF therapy combined with control of systemic inflammation achieves good visual and anatomical outcomes even though reactivation is common.² Ocular complications requiring separate management are common across etiologies: glaucoma requiring treatment was observed in roughly a third of eyes overall in one large cohort, more frequently in anterior uveitis and panuveitis, and cataract surgery was required in nearly 40% of eyes over the study period.¹

Complications

• Cystoid macular edema and chorioretinal scarring causing permanent central vision loss
• Exudative retinal detachment (acute VKH) or tractional/rhegmatogenous detachment from chronic inflammation
• Glaucoma requiring treatment, common across etiologies and especially in panuveitis¹
• Cataract, from both chronic inflammation and corticosteroid therapy, frequently requiring surgery¹
• Inflammatory choroidal neovascular membrane, particularly in chronic-recurrent VKH disease²

Clinical Pearls

• Posterior uveitis and panuveitis present with worse baseline visual acuity than anterior/intermediate uveitis, but often improve faster (by 1 year) with appropriate etiology-directed treatment¹
• Behçet's disease carries the worst long-term visual prognosis among major uveitis etiologies, reinforcing the importance of early aggressive treatment¹
• A systemic prodrome (headache, tinnitus, hearing changes) followed by later skin/hair changes (vitiligo, poliosis) should raise suspicion for VKH disease
• Inflammatory CNVM should be actively screened for in chronic-recurrent VKH disease, since prompt anti-VEGF therapy combined with systemic inflammation control produces good outcomes²
• Glaucoma and cataract are common complications across nearly all posterior uveitis/panuveitis etiologies and should be proactively monitored for, not treated as incidental findings¹

Common Pitfalls

• Treating posterior uveitis/panuveitis as a single disease entity rather than pursuing etiology-specific diagnosis and treatment
• Missing an infectious cause by moving straight to corticosteroid therapy without adequate exclusionary workup
• Underestimating Behçet's disease severity/urgency given its comparatively poor long-term visual prognosis
• Failing to screen for CNVM in chronic VKH disease, missing a treatable cause of vision decline
• Overlooking the high burden of glaucoma and cataract as expected complications requiring proactive monitoring across etiologies